Konrad Klinghammer

List of Publications by Year
in descending order

27 papers	544 citations	687220 13 h-index	642610 23 g-index
28 all docs	28 docs citations	28 times ranked	1148 citing authors

#	Article	IF	Citations
1	Predictors for Adherence to Treatment Strategies in Elderly HNSCC Patients. Cancers, 2022, 14, 423.	1.7	3
2	Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group. Frontiers in Oncology, 2022, 12, 730785.	1.3	1
3	Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study. European Journal of Cancer, 2022, 169, 146-155.	1.3	4
4	Multiparametric Phenotyping of Circulating Tumor Cells for Analysis of Therapeutic Targets, Oncogenic Signaling Pathways and DNA Repair Markers. Cancers, 2022, 14, 2810.	1.7	6
5	Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts. Cells, 2021, 10, 517.	1.8	20
6	Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets. International Journal of Cancer, 2021, 149, 1166-1180.	2.3	10
7	A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck â€" the RESGEX study. ESMO Open, 2021, 6, 100242.	2.0	5
8	A multilayered epithelial mucosa model of head neck squamous cell carcinoma for analysis of tumor-microenvironment interactions and drug development. Biomaterials, 2020, 258, 120277.	5.7	9
9	Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies. Cancers of the Head & Neck, 2020, 5, 9.	6.2	25
10	Distinct immune evasion in <scp>APOBEC</scp>â€enriched, <scp>HPV</scp>â€negative <scp>HNSCC</scp>. International Journal of Cancer, 2020, 147, 2293-2302.	2.3	10
11	Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma. British Journal of Cancer, 2020, 122, 835-846.	2.9	11
12	Support of a molecular tumour board by an evidence-based decision management system for precision oncology. European Journal of Cancer, 2020, 127, 41-51.	1.3	25
13	Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer. Oncotarget, 2020, 11, 3688-3697.	0.8	13
14	Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108). European Journal of Cancer, 2019, 122, 53-60.	1.3	16
15	A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers. International Journal of Cancer, 2018, 142, 156-164.	2.3	2
16	pN status predicts outcomes in surgically treated pT1â€"pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study. European Archives of Oto-Rhino-Laryngology, 2018, 275, 2787-2795.	0.8	6
17	Reactive oxygen species in cancer stem cells of head and neck squamous cancer. Seminars in Cancer Biology, 2018, 53, 248-257.	4.3	44
18	Choosing wisely â€" Preclinical test models in the era of precision medicine. Cancer Treatment Reviews, 2017, 55, 36-45.	3.4	37

#	Article	IF	Citations
19	Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer. International Journal of Cancer, 2017, 141, 1215-1221.	2.3	24
20	Animal models for personalized treatment options. International Journal of Clinical Pharmacology and Therapeutics, 2017, 55, 698-700.	0.3	6
21	Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. Oncotarget, 2016, 7, 75379-75393.	0.8	27
22	Targeted Therapy of Head and Neck Cancer. Oncology Research and Treatment, 2016, 39, 780-786.	0.8	17
23	A comprehensively characterized large panel of head and neck cancer patientâ€derived xenografts identifies the m<scp>TOR</scp> inhibitor everolimus as potential new treatment option. International Journal of Cancer, 2015, 136, 2940-2948.	2.3	53
24	PI3K/PTEN/AKT/mTOR polymorphisms: Association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximabâ€docetaxel. Head and Neck, 2015, 37, 471-478.	0.9	19
25	Developmental delay in hypoxia-induced HO-1 expression predisposes to gut injury. Journal of Perinatal Medicine, 2012, 40, 191-7.	0.6	6
26	Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximabâ€"Docetaxel Treatment. Clinical Cancer Research, 2011, 17, 5197-5204.	3.2	85
27	Association of Epidermal Growth Factor Receptor Polymorphism, Skin Toxicity, and Outcome in Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment. Clinical Cancer Research, 2010, 16, 304-310.	3.2	60